FOLH1 and neoplasm: Therefore, our anti-PSMA/anti-CD3 BsAb designs avoided bivalent CD3 binding and focused on developing the monovalent CD3-binding domain (scFv or Fab) to avoid inducing auto-activation of T cells without binding to tumor cells.